Ameritas Investment Partners’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$152K Buy
996
+416
+72% +$50.5K ﹤0.01% 1573
2026
Q1
$72.3K Hold
580
– – ﹤0.01% 1872
2025
Q4
$60.7K Sell
580
-120
-17% -$10.2K ﹤0.01% 1996
2025
Q3
$43.9K Hold
700
– – ﹤0.01% 2222
2025
Q2
$15.8K Buy
+700
New +$16.4K ﹤0.01% 2761
2021
Q2
– Sell
-38
Closed -$8K – 3252
2021
Q1
$8K Hold
38
– – ﹤0.01% 2931
2020
Q4
$8K Hold
38
– – ﹤0.01% 2892
2020
Q3
$6K Hold
38
– – ﹤0.01% 2941
2020
Q2
$9K Hold
38
– – ﹤0.01% 2786
2020
Q1
$7K Hold
38
– – ﹤0.01% 2706
2019
Q4
$11K Hold
38
– – ﹤0.01% 2714
2019
Q3
$10K Hold
38
– – ﹤0.01% 2764
2019
Q2
$14K Hold
38
– – ﹤0.01% 2660
2019
Q1
$10K Hold
38
– – ﹤0.01% 2708
2018
Q4
$8K Hold
38
– – ﹤0.01% 2750
2018
Q3
$17K Hold
38
– – ﹤0.01% 2596
2018
Q2
$15K Hold
38
– – ﹤0.01% 2673
2018
Q1
$21K Hold
38
– – ﹤0.01% 2404
2017
Q4
$23K Hold
38
– – ﹤0.01% 2373
2017
Q3
$16K Hold
38
– – ﹤0.01% 2545
2017
Q2
$15K Buy
+38
New +$11.1K ﹤0.01% 2629

Other funds holding PVLA

Ameritas Investment Partners's PVLA Position: Q2 2026 in Review

Ameritas Investment Partners increased its Palvella Therapeutics (PVLA) stake by 72% in Q2 2026, buying an estimated $50.5K and bringing the position to 996 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Ameritas Investment Partners first reported a position in PVLA in Q2 2017 and has held it in 21 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Ameritas Investment Partners held 996 shares of Palvella Therapeutics worth $152K as of Q2 2026.
  • Ameritas Investment Partners bought 416 Palvella Therapeutics shares in Q2 2026, an estimated $50.5K.
  • Palvella Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1573 holding.
  • Ameritas Investment Partners first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.